David Moadel

David Moadel

InvestorPlace Contributor

About David Moadel

David Moadel proudly serves as the Chief Analyst and Opportunity Researcher for Portfolio Wealth Global as well as a financial writer for InvestorPlace.com. David is also active on multiple social media platforms, with tens of thousands of followers on YouTube, Twitter, StockTwits, and other popular sites. His YouTube channel educates and informs a loyal crowd of followers on topics ranging from cryptocurrencies to stocks, options, precious metals, bonds, futures, and other areas of finance. With a master’s degree in education and decades of investing experience, David has the financial know-how and a passion for teaching that has boosted the bottom line of countless clients. Focusing on data rather than emotions, David is always on the lookout for new pathways to financial freedom. Count on David for wealth-building strategies and resources for investors and traders of all financial backgrounds.

Recent Articles

Out-of-Control Expenses Make It Hard to Smile About SmileDirectClub

By David Moadel, InvestorPlace Contributor

SDC stock may be the target of social media traders, but sensible investors should give the company a checkup before entering a position.

Lightning eMotors Stock Is a Buy on More Than Just Its Berkshire Connection

By David Moadel, InvestorPlace Contributor

ZEV stock's route to new highs will be powered by prime deals to produce zero-emission buses, powertrains, charging products and more.

REE Automotive Can Surprise Investors With a Comeback

By David Moadel, InvestorPlace Contributor

REE stock took a beating, but the low share price doesn't reflect future growth based on government funding and technology developments.

Tilray Anywhere Near $12 Is an Absolute Steal

By David Moadel, InvestorPlace Contributor

The skeptics will fret over a vote allowing more TLRY stock shares to be issued. Yet, this move will give Tilray more financial flexibility.

eFFECTOR Therapeutics Stock Might Be Worth the Risk in Small Quantities

By David Moadel, InvestorPlace Contributor

During the post-SPAC spectacle, EFTR stock be volatile - this should be expected. Still, eFFECTOR's oncology therapies look promising.

Load More